Resultados Do Novo Gw Cannabinoid Contra Diabetes E

[CanhamoMAN]

22/01/08

http://pr.cannazine.co.uk/content/view/113/27/

Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders Promising

Preparations underway for commencement of Phase II trials in 2008

Porton Down, UK, 22 January 2008: GW Pharmaceuticals plc (AIM: GWP) announces that it has generated highly promising results in both pre-clinical pharmacology studies and a Phase I trial of a new potential cannabinoid treatment for type 2 diabetes and related metabolic disorders.

This research is part of a programme being conducted by GW to evaluate selected cannabinoids in a range of therapeutic areas.

GW’s initial cannabinoid target in this field, delta-9-tetrahydrocannabivarin (THCV), has successfully completed extensive pre-clinical pharmacology studies and its first Phase I clinical trial.

The pre-clinical studies have yielded highly promising findings.

Recent results in several models of diabetes show desirable effects on plasma insulin, leptin and adiponectin levels, hormones of particular relevance to the development and treatment of diabetes, especially in obese individuals.

In addition, we have seen a reduction in total cholesterol with an increase in the proportion of HDL (good) cholesterol.

The recently completed Phase I trial was a randomised, double blind, placebo controlled, dose escalation, safety and tolerability study of single doses of THCV in twelve healthy volunteer subjects. This trial showed that the study medication was well tolerated at target therapeutic doses and demonstrated a satisfactory safety profile.

Following on from this first study, GW is now preparing for a Phase IIa multiple dose study in type 2 diabetic patients in 2008.

These recent results add to previous findings showing effects on body weight, body fat content, energy expenditure, food intake, and other obesity-related parameters.

Dr Stephen Wright, R&D Director of GW, said, “These new results confirm that GW’s proprietary plant-based cannabinoids have significant potential as treatments in this important branch of therapeutics. We are now ready to build upon the pre-clinical data, as well as the Phase I trial results, by entering Phase II proof of principle studies during 2008.”

Dr Geoffrey Guy, Chairman, said, ”This exciting research programme is a further example of the range of potential for GW’s cannabinoids as new medicines. We believe that our research in the field of metabolic disorders represents a significant opportunity for GW and that it has the potential to be an important new area for future collaboration

[CanhamoMAN]

Resultados para tratamentos novos do GW Cannabinoid para o diabetes disordens no metabolismo relacionados...

Preparações underway para o começo de experimentações da fase II em 2008

Porton Para baixo, Reino Unido, 22 Janeiro 2008: Plc dos farmacologistas do GW (ALVO: GWP) anuncia que gerou resultados altamente prometedores em estudos pre-clínicos do farmacologistas e em uma experimentação da fase I de um tratamento potencial novo do cannabinoid para o tipo 2 diabetes e relacionou disorders metabolic.

Esta pesquisa é parte de um programa que está sendo conduzido por GW para avaliar cannabinoids selecionados em uma escala de áreas terapeuticas

O alvo’inicial neste campo, delta-9-tetrahydrocannabivarin do cannabinoid do GW s (THCV), terminou com sucesso estudos pre-clínicos extensivos do pharmacology e sua primeiro experimentação clínica da fase I.

Os estudos pre-clínicos renderam achados promissores.

Os resultados recentes em diversos modelos do diabetes mostram efeitos desejáveis na insulina do plasma, os níveis do leptin e do adiponectin, os hormoneos da relevância particular ao desenvolvimento e o tratamento do diabetes, especial em indivíduos obesos.

Além, nós vimos uma redução no cholesterol total com um aumento na proporção do cholesterol (bom) de HDL.[qoute]cade a noticias disso????